đź’Š Update: Changes to Ribociclib (Kisqali) Storage & Packaging
We wanted to share an important update for anyone currently taking ribociclib (Kisqali), a targeted therapy used for HR-positive, HER2-negative breast cancer (early or advanced), often alongside hormone therapy. 🔄What’s changed? From early May, ribociclib tablets no longer need to be stored in the fridge. They can now be kept at room temperature (below 30°C). 📦During the transition period Some packs will still have the old refrigeration instructions Others will reflect the new room temperature guidance You may notice changes to packaging, including: A longer expiry date (up to 24 months) Different blister pack sizes A new layout showing how many tablets to take each day 💡Why the change? The medication itself has not changed. Updates to manufacturing and packaging now allow the tablets to be stored safely at room temperature. Because of this transition, both “old” (refrigerated) and “new” packs will be in circulation for a while. ✅What do you need to do? Always follow the storage instructions on your specific pack If your pack says to refrigerate, continue to do so until it’s finished Don’t be concerned if packaging looks different, the medicine remains the same Speak to your healthcare team if you have any questions or concerns For more information check out the following resources 👉Early breast cancer 👉Metastatic breast cancer As always, we’re here to support you. If you’ve noticed these changes or want to share your experience, please call our Helpline on 1800 500 258 Monday-Friday 9am-5pmBCNA welcomes pharmacy prescription changes for breast cancer medications
Six key breast cancer drugs are now more affordable thanks to 60-day prescribing. BCNA is pleased to confirm that six common types of hormone blocking therapies such as letrozole, anastrozole and tamoxifen, amongst others, are now able to be prescribed 60-days at a time, saving consumers time and money. “It is especially important that we work to reduce the cost of hormone blocking therapies for breast cancer as some are required for ten years or more after active treatment finishes,” said BCNA Director Policy, Advocacy & Support Services Vicki Durston. “Reducing the ongoing cost of these drugs will start to address financial toxicity and improve equity, especially for those in lower socioeconomic groups who already experience disparities in access to breast cancer care.” BCNA advocated strongly in support of 60-day prescribing last year, alongside other groups such as the Royal Australian College of General Practitioners. Read more via the link https://www.bcna.org.au/latest-news/bcna-news/bcna-welcomes-pharmacy-prescription-changes-for-breast-cancer-medications/ and also refer to the Department of Health and Aged Care information sheet https://www.health.gov.au/sites/default/files/2024-03/savings-with-60-day-prescriptions_0.pdf
